Cangene purchase propels Emergent Biosolution’s biodefense goals
Emergent Biosolutions Inc. took another step in its quest to expand its pipeline and ramp up commercial revenues by sealing a deal to acquire Canada’s Cangene Corp. for $222 million, or $3.24 per share on a fully diluted basis. The boards of directors of both companies approved the transaction, which gives Emergent three specialty products included in the U.S. Strategic National Stockpile and four commercial specialty therapies.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter